Tel Aviv, Israel, Nov. 03, 2026 (GLOBE NEWSWIRE) — Nexera Technologies Ltd (“Nexera” or the “Company”) (Nasdaq: NEXR, NEXRW), today announced that, as previously announced by its subsidiary, Fort Technology Inc. (Nasdaq: FRTT, TSXV: FORT) (“Fort”), the TSX Venture Exchange (“TSXV”) has approved the voluntary delisting of Fort’s common shares from the TSXV. The voluntary delisting from the TSXV will not affect the listing of the Fort’s common shares on the Nasdaq Capital Market (the “Nasdaq”), which will continue to trade on the Nasdaq under the symbol FRTT.

Fort believes that the trading volume of its shares on the TSXV no longer justifies the expenses and administrative efforts required to maintain a dual listing. Fort also believes that delisting from the TSXV will create a central marketplace for its common shares on the Nasdaq, and ultimately benefit the long-term liquidity and shareholder value of Fort.

It is anticipated that, effective as at the close of trading on or about November 6, 2026, Fort’s common shares will no longer be listed and posted for trading on the TSXV.

Following delisting from the TSXV, Fort’s shareholders can trade their common shares through their brokers on Nasdaq. As most brokers in Canada, including many discount and online brokers, have the ability to buy and sell securities listed on Nasdaq, Fort’s Nasdaq listing will continue to provide shareholders with accessibility to trade Fort’s common shares. Shareholders holding shares in Canadian brokerage accounts should contact their brokers to confirm how to trade Fort’s shares on the NASDAQ.

About Fort Technology

Fort is engaged in the retail sale of consumer products, primarily serving the pest control and remedial repair industries. Fort develops, markets and sells a range of products for both amateur and professional customers under its proprietary brands, including Roshield, Entopest, Rempro and BirdGo. Products are sold primarily through Amazon marketplaces in the United Kingdom and Europe as well as through other online sales channels. Fort currently serves customers throughout the United Kingdom and continental Europe and plans to expand its retail operations into the United States, subject to applicable regulatory approvals, including through the acquisition of Logia USA Inc., a company focused on selling advanced fuel integrity solutions for data centers and other mission-critical facilities in the United States.

About Nexera Technologies Ltd

Nexera Technologies Ltd operates, through its subsidiaries, in the fields of advanced technologies for the global homeland security, or HLS, sector and e-commerce. Its operations are conducted through three principal lines of business: KeepZone AI Inc., or KeepZone, a wholly-owned subsidiary dedicated to distributing and promoting AI-powered homeland security technologies, including 3D imaging and electromagnetic threat detection, perimeter intrusion detection, counter-unmanned aircraft systems, and multi-layered security solutions for critical infrastructure and global markets; Fort Products Limited, a legacy consumer products operation focused on pest control and remedial products, which was sold to Fort Technology Inc., or Fort Technology, in July 2025 in exchange for a controlling equity interest, with the Company having since reduced its stake in Fort while retaining control and strategic involvement in related e-commerce activities; and its ongoing legacy e-commerce activities, consisting of data-driven online retail operations (primarily on the Amazon Marketplace) conducted through the Company’s other wholly-owned subsidiaries, including Smart Repair Pro and Top Rank Ltd.

For more information on Nexera Technologies, visit: https://nexera-tech.io/

Forward-Looking Statements Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate,” or other comparable terms. For example, the Company is using forward-looking statements when discussing the expected timing of the voluntary delisting of Fort’s common shares from the TSXV; the anticipated benefits of the delisting, including creating a central marketplace for Fort’s common shares on Nasdaq and benefiting Fort’s long-term liquidity and shareholder value; the continued listing and trading of Fort’s common shares on the Nasdaq under the symbol FRTT; and shareholders’ continued ability to trade Fort’s common shares through their brokers on Nasdaq following the delisting. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the Company’s ability to adapt to significant future alterations in Amazon’s policies; the Company’s ability to sell its existing products and grow the Company’s brands and product offerings; the Company’s ability to meet its expectations regarding the revenue growth and the demand for e-commerce; the overall global economic environment; the impact of competition and new e-commerce technologies; general market, political and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; the impact of possible changes in Amazon’s policies and terms of use; the impact of conditions in Israel; and the other risks and uncertainties described in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (“SEC”), on April 1, 2026, and the Company’s other filings with the SEC. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contact

Michal Efraty
Adi and Michal PR-IR
Investor Relations, Israel
michal@efraty.com 

Lead pan-coronavirus program expected to file CTA/IND in 2H 2027
Optimized lead candidate shows potential for once-weekly dosing in preclinical studies
Cash on balance sheet of $8.1 million at September 30, 2026

CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) — Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs) to target major respiratory and high-consequence viral threats, today provided a business update for the third quarter ended September 30, 2026. During the quarter, Decoy advanced its lead pan-coronavirus program toward the clinic and identified an optimized lead candidate with potential for once-weekly dosing.

Third Quarter 2026 Highlights

  • Lead program timing: Decoy expects to file a Clinical Trial Application (CTA) or Investigational New Drug (IND) application in 2H 2027 to begin a Phase 1 trial of its pan-coronavirus candidate.
  • Manufacturing planning: Decoy is evaluating manufacturing locations and is in discussions with manufacturers of pulmonary delivery systems to support clinical development of its pan-coronavirus candidate.
  • Once-weekly dosing potential: In preclinical studies, the optimized lead candidate showed potential for once-weekly dosing, compared to daily dosing for earlier candidates.
  • Pan-filovirus program: Decoy is exploring a program targeting Ebola, Marburg and related viruses.
  • Non-dilutive funding: The Company has met with U.S. government and military agencies and has applied, or is applying, for several non-dilutive funding opportunities and strategic collaborations.
  • Cash on hand: $8.1 million on the balance sheet at September 30, 2026.

“We are making excellent progress toward the clinic with our pan-coronavirus program, and our AI-enabled IMP³ACT™ platform continues to rapidly produce potential drug candidates against some of the world’s deadliest viruses,” said Rick Pierce, Chief Executive Officer of Decoy Therapeutics. “We are focused on advancing these programs efficiently, including leveraging non-dilutive funding from top-tier collaborators.”

Pan-Coronavirus Program

Decoy’s lead program is designed to protect people at high risk from respiratory coronaviruses, including patients with chronic obstructive pulmonary disease (COPD), immunocompromised patients and transplant recipients. There are no approved therapies for endemic human coronaviruses. The program is partially funded by the Gates Foundation, and the Company plans to follow Phase 1 with a Phase 2a human challenge trial at hVivo, a contract research organization (CRO) based in the United Kingdom.

Less frequent dosing could improve adherence in high-risk patients and lower the Company’s cost of goods. D-MAVs are designed for use both before exposure (pre-exposure prophylaxis) and after exposure (post-exposure prophylaxis).

Pipeline and Funding

Decoy’s pan-filovirus program targets Ebola, Marburg and related viruses, and the Company is pursuing non-dilutive funding to support preclinical and clinical work across its programs. Decoy is also seeking strategic collaborations for its existing programs and new drug discovery partnerships, and seclidemstat, an investigational LSD1 inhibitor from the Company’s legacy oncology portfolio, is available for license or sale.

Financial Update

  • Cash on balance sheet was $8.1 million at September 30, 2026, including approximately $2.5 million in restricted Gates Foundation grant funding.
  • As of September 30, 2026, Decoy had 2,385,282 shares of common stock outstanding.

About Decoy Therapeutics

Decoy Therapeutics is a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs), a new category of antivirals engineered to target shared viral mechanisms, enabling a single, adaptable drug to work across many viruses. Built on the proprietary IMP³ACT platform, which combines AI-enabled design and rapid synthesis, Decoy develops peptide antivirals designed to move faster toward the clinic and expand what is possible in viral prevention and treatment. The Company’s lead candidates target many respiratory viruses, addressing the health and societal burden of viral disease.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Decoy, including expected achievement of milestones for its lead asset and future prospects of Decoy. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Decoy, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “can,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the Company will not obtain sufficient financing to execute on their business plans and risks related to Decoy’s products and development plans, including unanticipated issues with any IND application process and the potential of the IMP³ACT platform. Readers are urged to carefully review and consider the various disclosures made by the Company in its reports filed with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, Decoy’s actual results may vary materially from those expected or projected.

Media Contact

Tara Mulloy
TMC Studio
tara@tmc-studio.com
978-855-5219

WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) — Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced that Ron Renaud, President and Chief Executive Officer, and additional members of the management team will participate in the following investor conferences:

  • Stifel 2026 Healthcare Conference
    November 10-12, 2026, New York, NY
    Presentation: Tuesday, November 10, 2026, at 4:00 pm ET
  • Jefferies Global Healthcare Conference in London
    November 16-19, 2026, London, UK
    Fireside Chat: Monday, November 16, 2026, at 10:00 am GMT
  • 9th Annual Evercore Healthcare Conference
    November 30-December 2, 2026, Coral Gables, FL
    Fireside Chat: Wednesday, December 2, 2026, at 8:45 am ET

The live webcasts will be available on the Events page of Kailera’s investor website. A replay of the conference webcast will be archived on the company’s website for 90 days.

About Kailera Therapeutics
Kailera Therapeutics (Kailera) is a clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. With an obesity-first focus, Kailera is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for the greatest weight loss. Ribupatide injection is in global Phase 3 trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. Kailera is expanding the ribupatide franchise by developing a once-daily oral formulation with the goal of providing an oral option with the potential for compelling weight loss and highly differentiated tolerability. Additionally, Kailera is advancing the development of KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera’s vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. Kailera is based in Waltham, MA. For more information, visit www.kailera.com and follow us on LinkedIn and X.

Special Note Regarding Kailera Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the profile of product candidates, the potential of Kailera’s portfolio, market opportunities for product candidates, the competitive landscape, and participation in upcoming events. Forward-looking statements can be identified by terms such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “suggest,” “plan,” “goal,” “vision,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or similar expressions and the negatives of those terms. Kailera cannot assure you that the forward-looking statements in this press release will prove to be accurate. Information in this press release may also include statements relating to past performance, which should not be regarded as a reliable indicator of future performance. Forward-looking statements are based on current expectations and assumptions together with projections of the future which are inherently uncertain, and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, uncertainties inherent in clinical development, regulatory review, manufacturing, competition, market opportunities, reliance on third parties, estimates of capital requirements, needs for additional financing, and other important factors, including those discussed under the caption “Risk Factors” in Kailera’s filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release, and Kailera undertakes no obligation to update or revise any forward-looking statements. Kailera may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements.

Contact Information
Maura Gavaghan
Vice President, Investor Relations
maura.gavaghan@kailera.com

Anna Robinson
Vice President, Communications
anna.robinson@kailera.com

SHOEMAKERSVILLE, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) — Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent manufacturer and distributor of branded supplies and equipment for controlled environment agriculture (“CEA”), today provides additional detail on its debt elimination(i).

The Recapitalization:

Prior to these actions, the Company had a $109 million Term Loan, with approximately $12 million of annual debt service. In the recapitalization, the Term Loan was eliminated, and the former Term Loan Lenders received $27.5 million of a newly created class of Series 1 Non-Voting Convertible Preferred Stock, convertible to common stock at $1.00 per share, and warrants to purchase 27.5 million shares of common stock at an exercise price of $0.78 per share. In addition, Hydrofarm sold common stock and warrants to investors in a registered direct offering and concurrent private placement (the “Offering”), raising approximately $8.3 million in gross proceeds. Officers and directors of the Company participated in the Offering on the same terms as other investors. Following the Offering and conversion of the Preferred Stock, the Company will have approximately 41.8 million common shares outstanding.

Hydrofarm now has no outstanding debt(i) and enhanced liquidity, providing the Company with flexibility to support strategic initiatives and capitalize on market opportunities.

“This is a monumental time for Hydrofarm,” said Bill Toler, Chairman and Chief Executive Officer. “With no debt on our balance sheet, we enter our 50th year in 2027 independent and built to scale. We are also excited about the opportunity to sell our cultivation products directly to commercial cannabis growers, removing a long-standing market access barrier and creating a more robust channel for our products.”

Strategic Priorities:

Hydrofarm remains committed to drive high-quality revenue streams, improve profit margins and strengthen its financial position. The Company’s proprietary and partner brands span the CEA, gardening and agriculture markets. The Company has reduced costs and improved productivity within the organization. Now with the recapitalization complete, Hydrofarm is focused on sustainable growth through commercial direct offerings, organic brands, international expansion, ecommerce, and logistics services.

“The recapitalization reflects the commitment of our organization, former lenders, and investors to build a stronger financial foundation to scale the Hydrofarm platform,” said Eric Ceresnie, Senior Vice President of Corporate Development and International Markets. “We are a lean and focused organization with a capital structure to support growth. We are excited about expanding the direct commercial sales channel, scaling our logistics services platform, and pursuing additional growth opportunities. I’m proud of the resilience of our organization, investors, customers, and vendor partners have shown to get us here. Now we can execute and build.”

Nasdaq Listing Compliance and Other Information:

As previously disclosed, the Company was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in stockholders’ equity (the “Equity Rule”). Giving effect to the recapitalization and offering, the Company believes that the Company’s pro-forma stockholders’ equity exceeds the $2.5 million minimum, and that the Company has regained compliance with the Equity Rule. As previously disclosed, the Company was also not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1 per share (the “Bid Price Rule”). The Company remains subject to Nasdaq’s continued monitoring of its compliance with the Equity Rule and the other Nasdaq Listing Rules, including the Bid Price Rule, and there can be no assurance that Nasdaq will find that the Company has regained compliance with the Equity Rule or the Bid Price Rule, or that the Company will remain in compliance with the Nasdaq Listing Rules.

Additional information regarding the recapitalization is set forth in the Company’s Current Reports on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on October 27, 2026, and in the Company’s press releases dated October 27 and October 28, 2026.

The registered direct offering was made pursuant to an effective shelf registration statement on Form S-3 previously filed with the SEC and declared effective on December 10, 2025, the base prospectus dated December 10, 2025 thereunder and a prospectus supplement to the base prospectus filed on October 29, 2026 with the SEC. Copies of the final prospectus may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. The final prospectus was filed with the SEC and is available on the SEC’s website located at http://www.sec.gov.

The securities sold in the concurrent private placement, and the Series 1 Non-Voting Convertible Preferred Stock and warrants issued to the former Term Loan lenders, have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or state securities laws, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. Hydrofarm has agreed to file registration statements with the SEC covering the resale of those securities and the shares of common stock issuable upon their exercise or conversion. Any such resale will be made only by means of a prospectus.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is not a solicitation of a proxy. Stockholders are urged to read the Company’s proxy statement, when it becomes available, because it will contain important information.

Hydrofarm intends to file a proxy statement seeking among other things, shareholder approval of the conversion of the Series 1 Non-Voting Convertible Preferred Stock and the exercise of the warrants issued to the former Term Loan lenders, and to hold a shareholder meeting as promptly as practicable. The Company also intends to file registration statements covering the resale of securities issued in the private placement and to the former Term Loan lenders.

(i) Hydrofarm maintains an immaterial amount of ‘Other debt’ comprised of a foreign subsidiary’s revolving line of credit and mortgage.

About Hydrofarm Holdings Group, Inc.

Hydrofarm is a leading independent manufacturer and distributor of supplies and equipment for controlled environment agriculture, including plant nutrition, growing media, horticultural lighting and climate control solutions, spanning a portfolio of proprietary and select partner brands. The Company manufactures its proprietary plant nutrition and growing media brands at its manufacturing center of excellence in Eugene, Oregon, and, through its logistics services platform, provides third-party warehousing, fulfillment and distribution services across a wide range of industries. For nearly 50 years, Hydrofarm has helped growers make growing easier and more productive. The Company’s mission is to empower growers, farmers and cultivators with products that enable greater quality, efficiency, consistency and speed.

www.Hydrofarm.com

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “believe,” “expect,” “intend,” “anticipate,” “plan,” “will,” “project,” “potential” and similar expressions. They include, among others, statements regarding: the receipt of stockholder approval for the conversion of the Series 1 Non-Voting Convertible Preferred Stock and the exercise of the warrants issued to the former Term Loan lenders, and the timing of the related proxy statement and stockholder meeting; whether any warrants will be exercised and the amount of any additional proceeds therefrom; the timing of the filing and effectiveness of resale registration statements, if at all; the Company’s pro forma capitalization and stockholders’ equity; the Company’s belief that it has regained compliance with the Equity Rule and its ability to regain or maintain compliance with Nasdaq continued listing requirements, including the Bid Price Rule; the Company’s competitive position and the strength of its brand portfolio; the expected benefits of the consolidation of manufacturing into the Company’s Eugene, Oregon manufacturing center of excellence, including productivity and cost improvements; the ability to generate future growth, revenue and commercial opportunities from direct-to-cannabis grower sales following the elimination of restrictions under the Term Loan; the objectives, scope and anticipated results of Project Agility, including growth of the Company’s logistics services platform; the timing of the Company’s third quarter 2026 results; and the Company’s future financial performance, margins, liquidity and capital allocation plans.

These statements are based on management’s current expectations and assumptions. They are subject to risks and uncertainties that could cause actual results to differ materially, including: the risk that stockholders do not approve the conversion of the Series 1 Non-Voting Convertible Preferred Stock or the exercise of the warrants issued to the former Term Loan lenders, or that approval is delayed; the risk that the Company does not regain or maintain compliance with Nasdaq continued listing requirements, including the Equity and Bid Price Rules, and the risk that its securities could be delisted; the potential dilution to existing stockholders from the issuance of common stock, pre-funded warrants and common warrants to investors in the registered direct offering and concurrent private placement, and the issuance of the Series 1 Non-Voting Convertible Preferred Stock and common warrants to the former Term Loan lenders, and from any later conversion or exercise thereof; the impact on the market price of the common stock of future sales of shares; the risk that the Company cannot file or obtain effectiveness of the required resale registration statements; the final accounting treatment of the Series 1 Non-Voting Convertible Preferred Stock and the warrants issued in the transactions; the Company’s history of operating losses; demand conditions in the CEA and hydroponics markets; the Company’s ability to execute on Project Agility and its other growth initiatives including direct-to-cannabis grower sales; and the other factors described under “Risk Factors” in the Company’s Annual Report on Form 10-K and subsequent periodic reports filed with the SEC. Pro forma figures are unaudited and illustrative and are not necessarily indicative of the Company’s actual financial position. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update them except as required by law.

CONTACT: Contact: ir@hydrofarm.com

  • Q3 revenue increased 40% year-over-year to a record $252 million, driven by robust marketplace growth.
  • Q3 marketplace revenue increased 43% year-over-year, driven by expanding networks of buyers and suppliers and increasing wallet share.
  • Q3 gross profit increased 37% year-over-year to a record $98.7 million, driven by strong marketplace growth. Record Q3 marketplace gross margin of 36.0%, an increase of 30 bps year-over-year.
  • Q3 Adjusted EBITDA improved $15.3 million year-over-year to Adjusted EBITDA of $21.4 million, driven by strong marketplace gross profit growth and significant operating expense leverage.
  • Strong operating results were driven by consistent execution across growth initiatives: establishing Xometry as the infrastructure for custom manufacturing, improving AI-native marketplace experiences, expanding buyer and supplier networks, deepening enterprise engagement and leveraging services opportunities.

NORTH BETHESDA, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) — Xometry, Inc. (NASDAQ: XMTR), the global AI-native marketplace connecting buyers and suppliers of custom manufacturing, today announced its financial results for the third quarter ended September 30, 2026.

“Our key growth initiatives drove record results in the third quarter, with marketplace growth of 43% year-over-year, as we surpassed the $1 billion revenue run rate. We further improved our marketplace experience and continue to deepen enterprise engagement, driving record net buyer additions and increasing wallet share in larger accounts,” said Sanjeev Singh Sahni, CEO at Xometry. “We continue to strengthen Xometry’s position as the infrastructure layer for custom manufacturing, enabling us to rapidly scale online adoption and accelerate market share gains.”

“Our record-setting Q3 performance demonstrates the compounding growth and operational efficiency of our marketplace, delivering both strong revenue expansion and margin improvement,” said James Miln, CFO at Xometry. “Revenue growth remained robust at the 40% level for the second quarter in a row, alongside record marketplace gross margin of 36.0%. This durable top line growth was paired with yet another quarter of improved Adjusted EBITDA profit margin, up 510 basis points year-over-year to 8.5%.”                                                                                                    

Third Quarter 2026 Financial Highlights

  • Total revenue for the third quarter of 2026 was $252 million, an increase of 40% year-over-year.
  • Total gross profit for the third quarter of 2026 was $98.7 million, an increase of 37% year-over-year. Total gross margin for the third quarter of 2026 was 39.1%.
  • Marketplace revenue for the third quarter of 2026 was $238 million, an increase of 43% year-over-year.
  • Marketplace Active Buyers increased 20% from 78,282 as of September 30, 2025 to 93,812 as of September 30, 2026, with record net buyer additions of 4,255 in the third quarter of 2026.
  • Marketplace Accounts with Last Twelve-Months Spend of at least $50,000 increased 26% from 1,724 as of September 30, 2025 to 2,172 as of September 30, 2026.
  • Services revenue for the third quarter of 2026 was $14.4 million, up 2% year-over-year. 
  • Net income attributable to common stockholders for the third quarter of 2026 was $1.9 million, as compared to net loss attributable to common stockholders of $11.6 million in the third quarter of 2025.
  • Adjusted EBITDA for the third quarter of 2026 was $21.4 million, reflecting an improvement of $15.3 million year-over-year.
  • Non-GAAP net income for the third quarter of 2026 was $18.6 million, as compared to a Non-GAAP net income of $2.1 million in the third quarter of 2025. 
  • Cash, cash equivalents and marketable securities were $505 million as of September 30, 2026.

Third Quarter 2026 Business Highlights  

  • Xometry unveiled its next-gen Workcenter experience for manufacturing partners, building on the AI sourcing models introduced in July. The redesigned homepage unifies job discovery, performance scores and payout visibility, and the enhanced Job Board offers filters and an on-screen 3D viewer and drawing review.
  • Xometry expanded its partnership with TradeCentric, adding Purchase Order Automation and Invoice Automation to the PunchOut capability already available between its marketplace and customers’ eProcurement systems. The integration connects with over 220 eProcurement solutions, including Coupa, SAP Ariba and Microsoft Dynamics, and is available now to U.S. customers, with international expansion planned.
  • Xometry Foundation announced a partnership with MxD, the nation’s Digital Manufacturing and Cybersecurity Institute, aimed at making cybersecurity compliance, including CMMC Level 2, more affordable for small and mid-sized manufacturers. The grant program is part of Xometry’s broader commitment to strengthening the U.S. aerospace and defense industrial base. 
  • Xometry released data showing job growth among its Texas supplier partners tracking at nearly twice the rate of its national partner network in 2026, driven by demand for certified manufacturing capabilities.

Financial Summary
(In thousands, except per share amounts)
(Unaudited)

    For the Three Months
Ended September 30,
        For the Nine Months
Ended September 30,
     
    2026     2025     % Change   2026     2025     % Change
                           
Consolidated                                
Revenue   $ 252,439     $ 180,715     40 %   $ 686,857     $ 494,234     39 %
Gross profit     98,680       72,029     37 %     264,321       193,536     37 %
Net income (loss) attributable to common stockholders     1,935       (11,597 )   117 %     (8,645 )     (53,109 )   84 %
EPS, basic and diluted, of Class A and Class B common stock     0.03       (0.23 )   113 %     (0.16 )     (1.05 )   85 %
Adjusted EBITDA(1)     21,423       6,142     249 %     46,050       10,146     354 %
Non-GAAP net income(1)     18,561       2,103     783 %     35,362       656     5,291 %
Non-GAAP EPS, basic(1), of Class A and Class B common stock     0.32       0.04     700 %     0.65       0.01     6,400 %
Non-GAAP EPS, diluted(1), of Class A and Class B common stock     0.28       0.04     600 %     0.57       0.01     5,600 %
                                 
Marketplace                                
Revenue   $ 238,004     $ 166,592     43 %   $ 644,691     $ 451,168     43 %
Cost of revenue     152,306       107,086     42 %     417,787       295,891     41 %
Gross Profit   $ 85,698     $ 59,506     44 %   $ 226,904     $ 155,277     46 %
Gross Margin     36.0 %     35.7 %   0.3 %     35.2 %     34.4 %   0.8 %
                                 
Services                                
Revenue   $ 14,435     $ 14,123     2 %   $ 42,166     $ 43,066     (2 )%
Cost of revenue     1,453       1,600     (9 )%     4,749       4,807     (1 )%
Gross Profit   $ 12,982     $ 12,523     4 %   $ 37,417     $ 38,259     (2 )%
Gross Margin     89.9 %     88.7 %   1.2 %     88.7 %     88.8 %   (0.1 )%

(1) These non-GAAP financial measures, and the reasons why we believe these non-GAAP financial measures are useful, are described below and reconciled to their most directly comparable GAAP measures in the accompanying tables.

Key Operating Metrics(2):

    As of September 30,        
    2026     2025     %
Change
 
                   
Active Buyers(3)     93,812       78,282       20 %
Percentage of Revenue from Existing Accounts(3)     98 %     98 %      
Accounts with Last Twelve-Months Spend of at Least $50,000(3)     2,172       1,724       26 %

(2) These key operating metrics are for Marketplace. See “Key Terms for our Key Metrics and Non-GAAP Financial Measures” below for definitions of these metrics.
(3) Amounts shown for Active Buyers and Accounts with Last Twelve-Months Spend of at Least $50,000 are as of September 30, 2026 and 2025, and Percentage of Revenue from Existing Accounts is presented for the quarters ended September 30, 2026 and 2025.       

Financial Guidance and Outlook:

    Q4 2026  
    (in millions)  
    Low     High  
Revenue   $ 254     $ 256  
Adjusted EBITDA   $ 22.0     $ 22.5  
                 
  • For Q4 2026, we expect revenue of $254-$256 million, representing 32-33% growth year-over-year driven by approximately 35-36% marketplace growth.
  • For Q4 2026, we expect Adjusted EBITDA of $22-$22.5 million, an improvement from Adjusted EBITDA of $8.4 million in Q4 2025.
  • For Full Year 2026, we are raising our revenue growth outlook from previous guidance of 33-34% to at least 37% driven by approximately 41% marketplace growth.
  • For Full Year 2026, we expect Adjusted EBITDA of $68-$68.5 million, an improvement from an Adjusted EBITDA of $18.5 million in Full Year 2025.

Xometry’s fourth quarter and full year 2026 financial outlook is based on a number of assumptions that are subject to change and may be outside of its control. If actual results vary from these assumptions, Xometry’s expectations may change. There can be no assurance that Xometry will achieve these results.

Reconciliation of Adjusted EBITDA on a forward-looking basis to net loss, the most directly comparable GAAP measure, is not available without unreasonable efforts due to the high variability and complexity and low visibility with respect to certain charges excluded from this non-GAAP measure, including interest and dividend income, (provision) benefit for income taxes, charitable contributions of common stock and impairment of assets. Xometry expects the variability of these items could have a significant, and potentially unpredictable, impact on its future GAAP financial results.  

Use of Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”), Xometry, Inc. (“Xometry”, the “Company”, “we” or “our”) uses Adjusted EBITDA, non-GAAP net income and non-GAAP Earnings Per Share, basic and diluted, which are considered non-GAAP financial measures, as described below. These non-GAAP financial measures are presented to enhance the user’s overall understanding of Xometry’s financial performance and should not be considered a substitute for, nor superior to, the financial information prepared and presented in accordance with GAAP. The non-GAAP financial measures presented in this release, together with the GAAP financial results, are the primary measures used by the Company’s management and board of directors to understand and evaluate the Company’s financial performance and operating trends, including period-to-period comparisons, because they exclude certain expenses and gains that management believes are not indicative of the Company’s core operating results. Management also uses these measures to prepare and update the Company’s short and long term financial and operational plans, to evaluate investment decisions, and in its discussions with investors, commercial bankers, equity research analysts and other users of the Company’s financial statements. Accordingly, the Company believes that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating the Company’s operating results in the same manner as the Company’s management and in comparing operating results across periods and to those of Xometry’s peer companies. In addition, from time to time we may present adjusted information (for example, revenue growth) to exclude the impact of certain gains, losses or other changes that affect period-to-period comparability of our operating performance.

The use of non-GAAP financial measures has certain limitations because they do not reflect all items of income and expense, or cash flows, that affect the Company’s financial performance and operations. Additionally, non-GAAP financial measures do not have standardized meanings, and therefore other companies, including peer companies, may use the same or similarly named measures but exclude or include different items or use different computations. Management compensates for these limitations by reconciling these non-GAAP financial measures to their most comparable GAAP financial measures in the tables captioned “Reconciliations of Non-GAAP Financial Measures” included at the end of this release. Investors and others are encouraged to review the Company’s financial information in its entirety and not rely on a single financial measure.

Change in Non-GAAP Financial Measure

Effective January 1, 2026, we revised our definition of Non-GAAP Net Income to exclude depreciation expense which had previously been included as an adjustment. Management believes this revised definition provides a more representative view of our core operating performance. All prior-period amounts have been recast to conform to this new definition.

Key Terms for our Key Metrics and Non-GAAP Financial Measures

Marketplace revenue: includes the sale of parts and assemblies on our platform.

Services revenue: includes the sales of marketing and advertising services and, to a lesser extent, financial service products and SaaS-based solutions.

Active Buyers: The Company defines “buyers” as individuals who have placed an order to purchase on-demand parts or assemblies on our marketplace. The Company defines Active Buyers as the number of buyers who have made at least one purchase on our marketplace during the last twelve months.

Active Suppliers: The Company defines “suppliers” as individuals or businesses that have been approved by us to either manufacture a product on our platform for a buyer or have utilized our supplier services, including our digital marketing services, data services, financial services or tools and materials. The Company defines Active Suppliers as suppliers that have used our platform at least once during the last twelve months to manufacture a product.

Percentage of Revenue from Existing Accounts: The Company defines an “account” as an individual entity, such as a sole proprietor with a single buyer or corporate entities with multiple buyers, having purchased at least one part on our marketplace. The Company defines an existing account as an account where at least one buyer has made a purchase on our marketplace.

Accounts with Last Twelve-Month Spend of at Least $50,000: The Company defines Accounts with Last Twelve-Month Spend of at Least $50,000 as an account that has spent at least $50,000 on our marketplace in the most recent twelve-month period.

Adjusted earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA): The Company defines Adjusted EBITDA as net income (loss), adjusted for interest expense, interest and dividend income and other expenses, depreciation and amortization, amortization of lease intangible, provision for (benefit from) income taxes, stock-based compensation, payroll tax expense related to stock-based compensation, charitable contributions of common stock, income from unconsolidated joint venture, impairment of assets, restructuring charges and acquisition and other adjustments not reflective of the Company’s ongoing business, such as adjustments related to purchase accounting, the revaluation of contingent consideration, transaction costs and executive severance.

Non-GAAP net income: The Company defines non-GAAP net income as net loss adjusted for stock-based compensation, payroll tax expense related to stock-based compensation, amortization of lease intangible, amortization of deferred costs on convertible notes, charitable contributions of common stock, lease termination, impairment of assets, restructuring charges, loss on debt extinguishment, amortization of acquired intangible assets & patents, other amortization and acquisition and other adjustments not reflective of the Company’s ongoing business, such as adjustments related to purchase accounting, the revaluation of contingent consideration, transaction costs and executive severance.

Non-GAAP Earnings Per Share, basic and diluted (Non-GAAP EPS, basic and diluted): The Company calculates non-GAAP earnings per share, basic and diluted as non-GAAP net income divided by the weighted average number of basic or dilutive shares of common stock outstanding.

Management believes that the exclusion of certain expenses and gains in calculating adjusted EBITDA, non-GAAP net income and non-GAAP EPS, basic and diluted, provides a useful measure for period-to-period comparisons of the Company’s underlying core revenue and operating costs that is focused more closely on the current costs necessary to operate the Company’s businesses and reflects its ongoing business in a manner that allows for meaningful analysis of trends. Management also believes that excluding certain non-cash charges can be useful because the amount of such expenses is the result of long-term investment decisions made in previous periods rather than day-to-day operating decisions.

About Xometry
Xometry’s (NASDAQ: XMTR) AI-native marketplace, popular Thomasnet® industrial sourcing platform and suite of cloud-based services are rapidly digitizing the manufacturing industry. Xometry provides manufacturers the critical resources they need to grow their business and streamlines the procurement process for buyers through real-time pricing and lead time data. Learn more at xometry.com and xometry.eu.

Conference Call and Webcast Information
The Company will host a conference call and webcast to discuss the results at 8:30 a.m. ET (5:30 a.m. PT) on November 3, 2026. In addition to its press release announcing its third quarter 2026 financial results, Xometry will release an earnings presentation, which will be available on its investor website at investors.xometry.com.

Xometry, Inc. Third Quarter 2026 Earnings Presentation and Conference Call

Cautionary Information Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “would,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to, our beliefs regarding our financial position and operating performance, including our outlook and guidance for the fourth quarter of 2026 and the full year 2026; our expectations regarding our growth; and statements regarding our strategies, initiatives, products and platform capabilities. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks and uncertainties related to: competition, managing our growth, financial performance, our ability to forecast our performance due to our limited operating history, investments in new products or offerings, our ability to attract buyers and sellers to our marketplace, legal proceedings and regulatory matters and developments, any future changes to our business or our financial or operating model, our brand and reputation, and the impact of fluctuations in general macroeconomic conditions, such as fluctuations in inflation and rising interest rates. The forward-looking statements contained in this press release are also subject to other risks and uncertainties that could cause actual results to differ from the results predicted, including those more fully described in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2025, our Quarterly Reports on Form 10-Q, and other filings and reports that we may file from time to time with the SEC. All forward-looking statements in this press release are based on information available to Xometry and assumptions and beliefs as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law. 

   
Investor Contact: Media Contact:
Shawn Milne
VP Investor Relations
240-335-8132
shawn.milne@xometry.com
Lauran Cacciatori
VP Communications
773-610-0806
lauran.cacciatori@xometry.com
   

Xometry, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
(Unaudited)

    September 30,     December 31,  
    2026     2025  
Assets            
Current assets:            
Cash and cash equivalents   $ 18,132     $ 14,996  
Marketable securities     486,850       204,145  
Accounts receivable, less allowance for credit losses of $9.1 million and $8.0 million as of
September 30, 2026 and December 31, 2025, respectively
    152,151       97,370  
Inventory     3,767       3,917  
Prepaid expenses     6,216       7,262  
Other current assets     14,441       6,954  
Total current assets     681,557       334,644  
Software development and property and equipment, net     91,788       60,631  
Operating lease right-of-use assets     13,142       11,132  
Investment in unconsolidated joint venture     4,157       4,069  
Intangible assets, net     28,008       28,563  
Goodwill     268,051       263,801  
Other assets     913       880  
Total assets   $ 1,087,616     $ 703,720  
Liabilities and stockholders’ equity            
Current liabilities:            
Accounts payable and accrued cost of revenue   $ 68,870     $ 44,612  
Other accrued expenses     41,769       31,669  
Contract liabilities     17,667       10,319  
Income taxes payable     286       269  
Convertible notes, current portion     84,816       —  
Operating lease liabilities, current portion     3,012       2,067  
Total current liabilities     216,420       88,936  
Convertible notes, net of current portion     243,607       327,514  
Operating lease liabilities, net of current portion     11,198       9,841  
Deferred income taxes     123       145  
Other liabilities     1,349       547  
Total liabilities     472,697       426,983  
Commitments and contingencies            
Stockholders’ equity            
Preferred stock, $0.000001 par value. Authorized; 50,000,000 shares; zero shares issued
and outstanding as of September 30, 2026 and December 31, 2025
    —       —  
Class A common stock, $0.000001 par value. Authorized; 750,000,000 shares; 55,905,317
shares and 49,842,220 shares issued and outstanding as of September 30, 2026 and
December 31, 2025, respectively
    —       —  
Class B common stock, $0.000001 par value. Authorized; 5,000,000 shares; 1,475,311
shares issued and outstanding as of September 30, 2026 and December 31, 2025
    —       —  
Additional paid-in capital     1,058,186       710,925  
Treasury stock, at cost, 220,994 shares as of September 30, 2026 and December 31, 2025     (8,080 )     (8,080 )
Accumulated other comprehensive income     4,331       4,772  
Accumulated deficit     (440,661 )     (432,016 )
Total stockholders’ equity     613,776       275,601  
Noncontrolling interest     1,143       1,136  
Total equity     614,919       276,737  
Total liabilities and stockholders’ equity   $ 1,087,616     $ 703,720  
                 

Xometry, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(In thousands, except share and per share amounts)
(Unaudited)

    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
                   
Revenue   $ 252,439     $ 180,715     $ 686,857     $ 494,234  
Cost of revenue     153,759       108,686       422,536       300,698  
Gross profit     98,680       72,029       264,321       193,536  
Operating expenses:                        
Sales and marketing     35,571       32,649       101,124       88,866  
Operations and support     23,264       18,403       64,332       53,225  
Product development     16,102       12,524       40,510       34,703  
General and administrative     23,686       19,463       69,063       53,433  
Impairment of assets     —       49       —       49  
Total operating expenses     98,623       83,088       275,029       230,276  
Income (loss) from operations     57       (11,059 )     (10,708 )     (36,740 )
Other (expenses) income                        
Interest expense     (1,258 )     (1,278 )     (3,774 )     (3,648 )
Interest and dividend income     4,440       2,139       8,822       6,591  
Other expenses     (787 )     (1,636 )     (2,260 )     (19,882 )
Income from unconsolidated joint venture     187       220       588       544  
Total other income (expenses)     2,582       (555 )     3,376       (16,395 )
Income (loss) before income taxes     2,639       (11,614 )     (7,332 )     (53,135 )
(Provision) benefit for income taxes     (704 )     17       (1,306 )     25  
Net income (loss)     1,935       (11,597 )     (8,638 )     (53,110 )
Net income (loss) attributable to noncontrolling interest     —       —       7       (1 )
Net income (loss) attributable to common stockholders   $ 1,935     $ (11,597 )   $ (8,645 )   $ (53,109 )
                         
Net income (loss) per share of Class A and Class B common stock:                        
Basic   $ 0.03     $ (0.23 )   $ (0.16 )   $ (1.05 )
Diluted   $ 0.03     $ (0.23 )   $ (0.16 )   $ (1.05 )
                         
Weighted average shares outstanding:                        
Basic     57,333,901       50,920,588       54,508,819       50,653,997  
Diluted     60,462,719       50,920,588       54,508,819       50,653,997  
                         
Net income (loss)   $ 1,935     $ (11,597 )   $ (8,638 )   $ (53,110 )
Comprehensive income (loss):                        
Foreign currency translation     119       180       (441 )     4,766  
Total other comprehensive income (loss)     119       180       (441 )     4,766  
Comprehensive income (loss)     2,054       (11,417 )     (9,079 )     (48,344 )
Comprehensive (loss) income attributable to noncontrolling interest     (10 )     7       7       (17 )
Total comprehensive income (loss) attributable to common stockholders   $ 2,064     $ (11,424 )   $ (9,086 )   $ (48,327 )
                                 

Xometry, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)

    Nine Months Ended
September 30,
 
    2026     2025  
Cash flows from operating activities:            
Net loss   $ (8,638 )   $ (53,110 )
Adjustments to reconcile net loss to net cash used in operating activities:            
Depreciation and amortization     16,952       13,741  
Impairment of assets     —       49  
Reduction in carrying amount of right-of-use asset     1,771       3,350  
Lease termination     —       (14 )
Stock-based compensation     30,961       25,985  
Income from unconsolidated joint venture     (88 )     (144 )
Donation of common stock     4,404       2,080  
Loss on debt extinguishment     —       16,430  
Amortization of deferred costs on convertible notes     1,712       1,527  
Deferred tax benefit     (22 )     (44 )
Changes in other assets and liabilities:            
Accounts receivable, net     (55,096 )     (23,370 )
Inventory     79       (192 )
Prepaid expenses     1,039       (904 )
Other assets     (7,468 )     (1,233 )
Accounts payable and accrued cost of revenue     24,009       10,728  
Other accrued expenses     9,920       9,100  
Contract liabilities     7,395       3,170  
Lease liabilities     (1,482 )     (5,202 )
Other liabilities     (54 )     (24 )
Income taxes payable     16       (249 )
Net cash provided by operating activities     25,410       1,674  
Cash flows from investing activities:            
Purchases of marketable securities     (341,705 )     (6,571 )
Proceeds from sale of marketable securities     59,000       20,500  
Capitalization of software development and purchases of property and equipment     (38,905 )     (19,911 )
Cash paid for business combination     (4,599 )     —  
Net cash used in investing activities     (326,209 )     (5,982 )
Cash flows from financing activities:            
Proceeds from issuance of convertible notes     —       250,000  
Costs incurred in connection with issuance of convertible notes     —       (8,650 )
Payments for repurchase of convertible notes     —       (215,992 )
Purchase of capped calls     —       (17,475 )
Purchase of treasury stock     —       (8,080 )
Proceeds from stock options exercised     6,349       2,703  
Proceeds from issuance of common stock, net of underwriters’ discount     248,400       —  
Payment of costs related to issuance of common stock     (776 )     —  
Proceeds from issuance of common stock under Siemens agreement     50,000       —  
Net cash provided by financing activities     303,973       2,506  
Effect of foreign currency translation on cash and cash equivalents     (38 )     415  
Net increase (decrease) in cash and cash equivalents     3,136       (1,387 )
Cash and cash equivalents at beginning of the period     14,996       22,232  
Cash and cash equivalents at end of the period   $ 18,132     $ 20,845  
Supplemental cash flow information:            
Cash paid for interest   $ 1,796     $ 2,600  
Cash paid for income taxes     1,234       —  
Non-cash investing and financing activities:            
Stock-based compensation included in capitalized software development costs     7,117       —  
Non-cash consideration in connection with business combination     2,099       625  
Non-cash purchase of property and equipment     108       74  
Conversion of 2027 convertible notes to common stock     805       —  
                 

Xometry, Inc. and Subsidiaries
Reconciliations of Non-GAAP Financial Measures
(In thousands, except share and per share amounts)
(Unaudited)

    For the Three Months
Ended September 30,
    For the Nine Months
Ended September 30,
 
    2026     2025     2026     2025  
Adjusted EBITDA:                        
Net income (loss)   $ 1,935     $ (11,597 )   $ (8,638 )   $ (53,110 )
Add (deduct):                        
Interest expense, interest and dividend income and other expenses     (2,395 )     775       (2,788 )     16,939  
Depreciation and amortization(1)     6,185       5,000       16,952       13,741  
Amortization of lease intangible     —       180       —       540  
Provision (benefit) from income taxes     704       (17 )     1,306       (25 )
Stock-based compensation(2)     11,288       10,748       30,961       25,985  
Payroll tax expense related to stock-based compensation     728       366       2,792       2,100  
Acquisition and other(3)     28       —       309       927  
Charitable contribution of common stock     1,767       950       4,404       2,080  
Income from unconsolidated joint venture     (187 )     (220 )     (588 )     (544 )
Impairment of assets     —       49       —       49  
Restructuring charges(4)     1,370       (92 )     1,340       1,464  
Adjusted EBITDA   $ 21,423     $ 6,142     $ 46,050     $ 10,146  
                                 

    For the Three Months
Ended September 30,
    For the Nine Months
Ended September 30,
 
    2026     2025     2026     2025  
Non-GAAP Net Income:                        
Net income (loss)   $ 1,935     $ (11,597 )   $ (8,638 )   $ (53,110 )
Add (deduct):                        
Stock-based compensation(2)     11,288       10,748       30,961       25,985  
Payroll tax expense related to stock-based compensation     728       366       2,792       2,100  
Amortization of lease intangible     —       180       —       540  
Amortization of deferred costs on convertible notes     571       590       1,712       1,527  
Acquisition and other(3)     28       —       310       926  
Charitable contribution of common stock     1,767       950       4,404       2,080  
Lease termination     —       16       —       (14 )
Impairment of assets     —       49       —       49  
Restructuring charges(4)     1,370       (92 )     1,340       1,464  
Loss on debt extinguishment     —       —       —       16,430  
Amortization of acquired intangible assets & patents(5)     874       804       2,481       2,411  
Other amortization(5)     —       89       —       268  
Non-GAAP Net Income   $ 18,561     $ 2,103     $ 35,362     $ 656  
                         
Adjustments to numerator   $ 540     $ —     $ 1,619     $ —  
Weighted-average number of shares outstanding used to compute Non-GAAP Net Income (Loss) per share, basic and diluted, of Class A and Class B common stock     57,333,901       50,920,588       54,508,819       50,653,997  
Non-GAAP effect of potentially dilutive Class A common stock     9,969,202       3,115,487       9,902,171       2,608,839  
Non-GAAP weighted-average shares used to compute Non-GAAP Net Income (Loss) per share, diluted     67,303,103       54,036,075       64,410,990       53,262,836  
                         
EPS, basic and diluted, of Class A and Class B common stock   $ 0.03     $ (0.23 )   $ (0.16 )   $ (1.05 )
Non-GAAP EPS basic, of Class A and Class B common stock   $ 0.32     $ 0.04     $ 0.65     $ 0.01  
Non-GAAP EPS diluted, of Class A and Class B common stock   $ 0.28     $ 0.04     $ 0.57     $ 0.01  

(1) Represents depreciation expense of the Company’s long-lived tangible assets and amortization expense of its finite-lived intangible assets, as included in the Company’s GAAP results of operations.
(2) Represents the non-cash expense related to stock-based awards granted to employees, as included in the Company’s GAAP results of operations.
(3) Includes adjustments related to purchase accounting, the revaluation of contingent consideration, transaction costs and executive severance.
(4) Costs associated with the 2026 and 2025 reductions in workforce.
(5) In the first quarter of 2026, we changed the definition of Non-GAAP Net Income to exclude depreciation expense. Prior period amounts were recast to conform to the new definition.

Xometry, Inc. and Subsidiaries
Reconciliation of GAAP EPS to Non-GAAP EPS
(Unaudited)

    For the Three Months
Ended September 30,
    For the Nine Months
Ended September 30,
 
    2026     2025     2026     2025  
Non-GAAP EPS:                        
GAAP EPS, diluted, of Class A and Class B common stock   $ 0.03     $ (0.23 )   $ (0.16 )   $ (1.05 )
Non-GAAP effect of potentially dilutive Class A common stock     —       0.02       0.05       0.03  
Add (deduct):                        
Stock-based compensation     0.17       0.20       0.48       0.49  
Payroll tax expense related to stock-based compensation     0.01       0.01       0.04       0.04  
Amortization of lease intangible     —       —       —       0.01  
Amortization of deferred costs on convertible notes     0.01       0.01       0.03       0.03  
Acquisition and other     —       —       —       0.02  
Charitable contribution of common stock     0.03       0.02       0.07       0.04  
Impairment of assets     —       —       —       —  
Restructuring charges     0.02       —       0.02       0.03  
Loss on debt extinguishment     —       —       —       0.31  
Amortization of acquired intangible assets & patents     0.01       0.01       0.04       0.05  
Other amortization     —       —       —       0.01  
Non-GAAP EPS, diluted, of Class A and Class B common stock   $ 0.28     $ 0.04     $ 0.57     $ 0.01  
                                 

Xometry, Inc. and Subsidiaries
Segment Results
(In thousands)
(Unaudited)

    For the Three Months
Ended September 30,
    For the Nine Months
Ended September 30,
 
    2026     2025     2026     2025  
Segment Revenue:                  
U.S.   $ 213,392     $ 151,093     $ 580,357     $ 414,646  
International     39,047       29,622       106,500       79,588  
Total revenue   $ 252,439     $ 180,715     $ 686,857     $ 494,234  
                         
Segment Cost of Revenue:                  
U.S.   $ 130,596     $ 90,933     $ 357,882     $ 251,841  
International     23,163       17,753       64,654       48,857  
Total cost of revenue   $ 153,759     $ 108,686     $ 422,536     $ 300,698  
                         
Segment Adjusted EBITDA:                        
U.S.   $ 22,020     $ 10,349     $ 52,769     $ 20,234  
International     (597 )     (4,207 )     (6,719 )     (10,088 )
Total Adjusted EBITDA   $ 21,423     $ 6,142     $ 46,050     $ 10,146  
                                 

Xometry, Inc. and Subsidiaries
Supplemental Information
(In thousands)
(Unaudited)

    For the Three Months
Ended September 30,
    For the Nine Months
Ended September 30,
 
    2026     2025     2026     2025  
Summary of Stock-based Compensation Expense and Payroll Taxes Related to Stock-Based Compensation Expense                  
Sales and marketing   $ 2,694     $ 3,170     $ 7,201     $ 7,809  
Operations and support     2,839       3,712       8,552       9,450  
Product development     1,250       2,583       4,036       6,410  
General and administrative     5,233       1,649       13,964       4,416  
Total stock-based compensation expense and payroll taxes related to stock-based compensation   $ 12,016     $ 11,114     $ 33,753     $ 28,085  
                         
Summary of Depreciation and Amortization Expense                        
Cost of revenue   $ 179     $ 184     $ 538     $ 550  
Sales and marketing     805       799       2,384       2,385  
Operations and support     76       46       145       129  
Product development     5,060       3,723       13,353       9,860  
General and administrative     65       248       532       817  
Total depreciation and amortization expense   $ 6,185     $ 5,000     $ 16,952     $ 13,741  
                         
Summary of Restructuring Charges                        
Sales and marketing   $ 190     $ (27 )   $ 190     $ 62  
Operations and support     429       (108 )     431       718  
Product development     731       11       733       510  
General and administrative     20       32       (14 )     174  
Total restructuring charges   $ 1,370     $ (92 )   $ 1,340     $ 1,464  

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES.

VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) — JZR Gold Inc. (TSXV: JZR) (OTCPK: JZRIF) (the “Company” or “JZR”) is pleased to announce that, on October 29, 2026, an additional 15 tonnes of gold concentrate has been delivered to Recuperadora Brasileira de Metal (“RBM”), a precious metals refining and recovery plant located in São Paulo, Brazil. This brings the total gold concentrate delivered to RBM to 26 tonnes, including the initial shipment of 11 tonnes.

JZR has contracted RBM to process the gold concentrate derived from the Vila Nova Gold Property located in the State of Amapa, Brazil. RBM has completed the setup and testing of its leaching and carbon-in-leach (CIL) circuit, which is fully operational.

Processing of all 26 tonnes of gold concentrate is underway. The Company expects to receive results confirming the quantity of gold within the next two weeks.

JZR is a party to a Joint Venture Royalty Agreement (“JVRA”) dated July 6, 2020, as amended, with ECO Mineracao Oil and Gaz Drilling and Exploration EIRELI (“ECO”), pursuant to which JZR is entitled to receive 50% of the Net Profit Interest (as defined in the JVRA) in respect of the total sale value of all gold from the tailings piles and dams, pond basin and waste dumps on the Vila Nova property.

Rob Klenk, CEO of JZR Gold, commented: “We are extremely excited to reach this point in JZR’s history. With all 26 tonnes delivered and processing underway, we are advised that ECO is on the verge of generating the first gold revenue, from which the company expects to receive its entitled royalty payment interest. This is a transformational milestone for JZR and our shareholders. We look forward to receiving results from the refining process over the next two weeks and sharing those numbers with our shareholders.”

About JZR Gold Inc.

JZR Gold Inc. is focused on working with ECO to advance the Vila Nova Gold Project in Amapá State, Brazil. The Company has assumed operatorship of the Project and is focused on establishing reliable processing operations utilizing the existing permitted processing facility and associated infrastructure.

For further information, please contact:

Robert Klenk
Chief Executive Officer
rob@jzrgold.com

Forward-Looking Information

This news release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the Company’s plans and objectives for the Vila Nova Gold Project, increasing operating hours of the processing facility, statements regarding the Company’s plans to improve efficiency, achieving consistent and sustained production, and the Company’s expectations regarding the future performance of the Project. Forward-looking statements are based on management’s current expectations and assumptions and are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such statements. Readers are cautioned not to place undue reliance on forward-looking statements. JZR Gold undertakes no obligation to update such statements except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

None of the securities of JZR have been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law, and may not be offered or sold in the United States or to, or for the account or benefit of, persons in the United States or “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act) absent registration or an exemption from such registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy in the United States nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

NEW HAVEN, Conn., Nov. 03, 2026 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD) today announced that on November 1, 2026, Invivyd granted seven newly hired non-executive employees options to purchase an aggregate of 175,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan. 

The options have a per share exercise price of $0.5817, representing the closing price of Invivyd’s common stock on October 30, 2026, the last trading date prior to the date of grant. Each option vests over four years, with 25% of the shares subject to such option vesting on the first anniversary of the employee’s start date and the remaining shares vesting in equal monthly installments thereafter, in each case, subject to the employee’s continuous service with Invivyd. The options have a 10-year term and are subject to the terms of the Invivyd, Inc. 2026 Inducement Plan. 

About Invivyd   

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.  

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release. 

Contacts: 

Media Relations 
(781) 208-0160 
media@invivyd.com 

Investor Relations 
(781) 208-1747 
investors@invivyd.com 

TORONTO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Labrador Gold Corp. (TSX.V: LAB | FNR: 2N6) (“LabGold” or the “Company”) announces that, effective today, Raymond D. Harari, a director of LabGold, has been appointed as President of the Company, and that Robert Mason has been appointed as Corporate Secretary.

“I am delighted to welcome Ray as President and Rob as Corporate Secretary of LabGold,” said Roger Moss, Chief Executive Officer of LabGold. “Since joining the Board of Directors in mid-October, Ray has already made an immense contribution to the Company, bringing a fresh perspective, tremendous energy and a wealth of capital markets experience. His impact has been immediate, and I am confident that his expanded leadership role will be instrumental as we evaluate strategic opportunities and position LabGold for its next phase of growth. Rob’s extensive experience in securities law, corporate governance and mining transactions further strengthens our team at an important time for the Company. I look forward to working closely with both Ray and Rob as we pursue our shared objective of maximizing shareholder value.”

Mr. Harari is the founder of Canalis Capital, a Panama-based merchant banking firm focused on the natural resources sector. He has extensive experience in corporate finance, capital markets and strategic transactions, having held senior executive and board positions with numerous publicly traded mineral exploration companies throughout his career.

Mr. Mason is the founder and principal of Mason Law, a Toronto-based law firm specializing in corporate and securities law, mergers and acquisitions, and mining transactions. Mr. Mason has over 25 years of experience advising publicly traded companies, institutional investors and boards of directors on corporate finance, capital markets transactions, strategic acquisitions and corporate governance matters.

To create vacancies for the appointments of Messrs. Harari and Mason, Dr. Roger Moss has resigned as President, remaining as the Company’s Chief Executive Officer and director, and Mr. Bill Johnstone has resigned as corporate secretary. The Company thanks Mr. Johnstone for his six plus years of service to LabGold.

About Labrador Gold

Labrador Gold is a Canadian-based hybrid mining and investment issuer focused on the acquisition and exploration of prospective mineral projects in Canada and on strategic investments in mining companies and assets that the Company believes have the potential to generate long-term value.

The Mariposa project covers 16,000 ha in the White Gold District and is 40 kilometres southeast of the White Gold Project and 30 kilometres east-northeast of Fuerte’s Coffee gold project. Mariposa shares many geological similarities to both the Golden Saddle (part of the White Gold Project) and Coffee gold deposits including host lithologies, mineralization style and structural control. The property occurs at the headwaters of significant placer gold producing creeks with historic placer production of 73,000 oz from Scroggie Creek (3) indicative of significant bedrock gold mineralization yet to be fully defined. Six significant gold occurrences have been delineated by over 13,000 soil samples to date, including the most advanced Skookum Main and Skookum West prospects. LabGold has the option to earn a 100% interest in the Mariposa project from Pacific Ridge Exploration Ltd.

The Watson Project, a 70:30 joint venture with Nemo Resources Inc., represents the largest landholding in the Fort Hope Greenstone Belt which is significantly underexplored compared to other greenstone belts (e.g. Red Lake and Pickle Lake) in northwestern Ontario. While the exploration focus will be on gold, the Watson project also hosts significant potential for critical minerals (e.g. antimony, nickel, copper and zinc). The proposed road to the Ring of Fire, expected to begin construction in mid-2026, runs through the Watson property and, once complete, will significantly reduce exploration and development costs.

The 100% owned Hopedale property covers much of the Archean-age Florence Lake greenstone belt, which extends over 60 kilometers. While typical of greenstone belts globally, the area has been underexplored. LabGold’s work to date has identified gold anomalies in rocks, soils, and lake sediments across a three-kilometer section of the northern portion of the belt. Five gold occurrences lie along this trend, four of which were discovered by LabGold. Additional anomalous gold values occur across approximately 40 kilometers of the southern portion of the belt. Recent exploration has also demonstrated potential for copper, nickel, and cobalt.

The 100% owned Borden Lake project near Chapleau, Ontario lies immediately southeast of Discovery Silver Corp’s Borden gold mine. Past exploration by LabGold identified two anomalous gold zones based on geochemistry and geophysics.

The Company has 286,012,288 common shares issued and outstanding and trades on the TSX Venture Exchange under the symbol LAB.

For more information, please contact:

Roger Moss, CEO and Director
Tel: 416-704-8291
Email: rmoss@labradorgold.com

Website: www.labradorgold.com
X: @LabGoldCorp

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. Forward-looking information is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including management’s perceptions of historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. Any such forward-looking information is based on information currently available to LabGold and is based on assumptions and analyses made in light of LabGold’s experience and perception of historical trends and current conditions. While the Company considers these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. Readers are cautioned that actual results may vary from the forward-looking information, and undue reliance should not be placed on such forward-looking information.

By their nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. Additional risk factors can also be found in LabGold’s financial statements and management’s discussion and analysis, which are available under LabGold’s profile on SEDAR+ at www.sedarplus.ca.

Unless otherwise indicated, the forward-looking statements in this news release are based on the Company’s expectations at the date of this news release. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. LabGold undertakes no obligation to update or revise such forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise, except as required by applicable law.

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will participate in three upcoming investor conferences:

  • 3rd Annual Guggenheim Healthcare Innovation Conference; fireside chat on Tuesday, November 10, 2026, at 2:00 p.m. ET
  • 2026 Jefferies Global Healthcare Conference in London; presentation on Tuesday, November 17, 2026, at 10:30 a.m. ET / 3:30 p.m. GMT
  • 9th Annual Evercore Healthcare Conference; fireside chat on Tuesday, December 1, 2026, at 9:35 a.m. ET

Live webcasts of the events will be available in the Investors section of the Maze Therapeutics website at www.mazetx.com and archived for 60 days following the presentations.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor in Phase 2 development with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow Maze on LinkedIn and X.

IR/Corporate Contact:
Argot Partners
maze@argotpartners.com

Media Contact:
Amanda Lazaro, 1AB Media
Amanda@1ABMedia.com

Seyond at SCEWC26

Combining comprehensive LiDAR sensing, agentic AI-powered analytics, and technology collaborations to advance smart cities, critical infrastructure and safe spaces.

SUNNYVALE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — Seyond, a global provider of high-performance LiDAR solutions, is expanding its smart city and smart spaces solutions through advanced 3D sensing and technology collaborations. By connecting spatial data with agentic AI-powered analytics and computing platforms, Seyond helps organizations improve safety, transportation, and infrastructure operations.

Growing Demand for Smart Cities and Intelligent Infrastructure

Smart cities are becoming an operational priority as organizations seek real-time intelligence to improve safety, transportation and operational efficiency. According to LP Information, the global smart-city LiDAR market was valued at approximately $358 million in 2025, with a projected compound annual growth rate of 18.7%, suggesting a market of approximately $425 million in 2026.

Demand for spatial intelligence now extends beyond roadways to airports, stadiums, utilities, data centers, and other critical infrastructures. These applications create opportunities to better understand movement, optimize space utilization, and improve operations.

Based on industry research and internal assumptions, Seyond estimates an illustrative annual serviceable addressable market of $1.3 billion to $2.0 billion in 2026 for expanded stationary LiDAR applications outside China. This sensor-focused estimate represents potential market opportunity, not projected company revenue.

Seyond: Enabling Spatial Intelligence Across Smart Environments

Seyond’s comprehensive LiDAR portfolio, spanning ultra-long-range to short-range sensing, supports applications from transportation infrastructure to localized indoor and outdoor environments. Its technology generates high-resolution 3D spatial data to measure vehicle movement, pedestrian flows, and environmental activity without relying on identifiable photographic imagery, providing a privacy-conscious foundation for spatial analytics.

These capabilities support continuous spatial awareness across intersections, transportation hubs, commercial facilities, and public gathering spaces. Combined with AI-powered analytics and computing platforms, Seyond’s sensing technology helps organizations translate physical-world data into actionable insights, enabling more responsive infrastructure and better-informed operational decisions.

Expanding Technology Collaborations to Deliver Complete Operational Twin Solutions

Delivering practical smart city solutions increasingly requires collaboration across sensing, computing, AI, and software. One example is the digital operational twins, dynamic digital representation of a physical environment that reflects activity and movement in real time, helping operators understand changing conditions and make informed decisions.

At Smart City Expo World Congress 2026, November 3–5 in Barcelona, Seyond will participate as an exhibition partner at the Dell Technologies booth, showcasing a live LiDAR-powered operational twin.

By combining Seyond’s sensing capabilities with technologies from Dell and NVIDIA, the demonstration will illustrate how integrated solutions can support pedestrian-flow analysis, space utilization, and real-time operational awareness. The solution will feature a Dell Technologies system powered by the NVIDIA DGX Spark, which combines a 20-core Arm Grace CPU with an NVIDIA Blackwell GPU. Fused data from LiDAR, video, and other sensors feeds a live operational twin, giving operators a unified view of activity across the environment. The solution integrates vision AI agents built with NVIDIA Metropolis Blueprint for video search and summarization (VSS) and NVIDIA Cosmos to enhance scene understanding and support informed operational decisions.

Seyond is also collaborating with AMSYS to advance integrated spatial intelligence solutions for large-scale venues and public environments. Combining Seyond’s LiDAR sensing with the AMSYS Fusion Core Perception Platform, these solutions are designed to translate anonymous movement and occupancy data into actionable operational insights.

In a stadium or major event venue, for example, this approach could help operators monitor crowd density, analyze queues, and identify congestion across entrances and gathering areas. These insights could support better decisions about staffing, crowd movement, and resource allocation while maintaining a privacy-conscious approach to sensing.

Together, these collaborations demonstrate Seyond’s expanding role in connecting advanced sensing with AI, computing, and operational software. As investment in intelligent infrastructure grows, Seyond remains focused on bringing practical spatial intelligence solutions to cities, critical infrastructure and safe spaces.

About Seyond

Seyond is a global provider of high-performance LiDAR solutions for automotive, robotics, intelligent transportation, smart infrastructure, and other applications. Its comprehensive portfolio of advanced 3D sensing technologies enables accurate, reliable spatial intelligence across a wide range of environments.

For more information, visit www.seyond.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c501796e-599d-478e-86ec-4c3044e91d56

CONTACT: Seyond Media contact:

pr@seyond.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.